Pharmacological strategies to overcome treatment resistance in acute myeloid leukemia: increasing leukemic drug exposure by targeting the resistance factor SAMHD1 and the toxicity factor Top2β

Expert Opin Drug Discov. 2021 Jan;16(1):7-11. doi: 10.1080/17460441.2020.1811672. Epub 2020 Aug 31.
No abstract available

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anthracyclines / pharmacology
  • Antineoplastic Agents / pharmacology*
  • Cytarabine / pharmacology
  • DNA Topoisomerases, Type II / metabolism
  • Drug Resistance, Neoplasm
  • Humans
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / pathology
  • Molecular Targeted Therapy
  • Poly-ADP-Ribose Binding Proteins / metabolism
  • SAM Domain and HD Domain-Containing Protein 1 / metabolism

Substances

  • Anthracyclines
  • Antineoplastic Agents
  • Poly-ADP-Ribose Binding Proteins
  • Cytarabine
  • SAM Domain and HD Domain-Containing Protein 1
  • SAMHD1 protein, human
  • DNA Topoisomerases, Type II
  • TOP2B protein, human